What is COMIRNATY KP.2 and what is it used for?

Comirnaty KP.2 is a vaccine that has been developed by BioNTech and Pfizer. This vaccine has been adapted to target the KP.2 COVID-19 variant.

Comirnaty KP.2 30 microgram/dose dispersion for injection is indicated for active immunsation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.

The vaccine causes the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty KP.2 does not contain the virus to produce immunity, it cannot give you COVID-19.


Reference Information

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for COMIRNATY KP.2 visit the electronic Medicines Compendium (eMC).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you are concerned about a side-effect, it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/lot number if available.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.